Hydrogen sulfide signalling in neurodegenerative diseases
British Journal of Pharmacology · 2026-01 · 183 (1) · 83-100
DOI: 10.1111/bph.16170 ↗At a glance
Übersichtsarbeit in British Journal of Pharmacology, 2026-01. Written by Sunil Jamuna Tripathi and 4 co-authors. Institution: Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Major MEDLINE topics: Hydrogen Sulfide, Neurodegenerative Diseases, Signal Transduction. Cited 43 times so far (Crossref); 190 references. The full text is freely available in PubMed Central. Funded by: NIA NIH HHS, NIGMS NIH HHS, NIDA NIH HHS.
Abstract (original language)
The gaseous neurotransmitter hydrogen sulfide (H 2 S) exerts neuroprotective efficacy in the brain via post‐translational modification of cysteine residues by sulfhydration, also known as persulfidation. This process is comparable in biological impact to phosphorylation and mediates a variety of signalling events. Unlike conventional neurotransmitters, H 2 S cannot be stored in vesicles due to its gaseous nature. Instead, it is either locally synthesized or released from endogenous stores. Sulfhydration affords both specific and general neuroprotective effects and is critically diminished in several neurodegenerative disorders. Conversely, some forms of neurodegenerative disease are linked to excessive cellular H 2 S. Here, we review the signalling roles of H 2 S across the spectrum of neurodegenerative diseases, including Huntington's disease, Parkinson's disease, Alzheimer's disease, Down syndrome, traumatic brain injury, the ataxias, and amyotrophic lateral sclerosis, as well as neurodegeneration generally associated with ageing. LINKED ARTICLES This article is part of a themed issue Recent Innovations in Targeting Redox Biology for Therapeutics. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v183.1/issuetoc
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Brain Health Medicines Center, Harrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
- Department of Psychiatry, Case Western Reserve University, Cleveland, Ohio, USA.
- Geriatric Psychiatry, GRECC, Louis Stokes Cleveland VA Medical Center; Cleveland, Ohio, USA.
- School of Medicine, Institute for Transformative Molecular Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
- Department of Pathology, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
ORCID profiles: Bindu D Paul
Funding
- NIA NIH HHS
- NIGMS NIH HHS
- NIDA NIH HHS
- BLRD VA
- Case Western Reserve University Rebecca E. Barchas, M.D., Endowed Professorship in Translational Psychiatry
- Catalyst Award, Johns Hopkins University
- Department of Veterans Affairs Merit Award
- Elizabeth Ring Mather & William Gwinn Mather Fund
Cite
APA
Tripathi, S. J., Chakraborty, S., Miller, E., Pieper, A. A., & Paul, B. D. (2026). Hydrogen sulfide signalling in neurodegenerative diseases. British Journal of Pharmacology. https://doi.org/10.1111/bph.16170
Vancouver
Tripathi SJ, Chakraborty S, Miller E, Pieper AA, Paul BD. Hydrogen sulfide signalling in neurodegenerative diseases. British Journal of Pharmacology. 2026. doi:10.1111/bph.16170
BibTeX
@article{Tripathi2026,
author = {Tripathi, Sunil Jamuna and Chakraborty, Suwarna and Miller, Emiko and Pieper, Andrew A and Paul, Bindu D},
title = {Hydrogen sulfide signalling in neurodegenerative diseases},
journal = {British Journal of Pharmacology},
year = {2026},
doi = {10.1111/bph.16170}
}
EUVIMED